text-only page produced automatically by Usablenet Assistive Skip all navigation and go to page content Skip top navigation and go to directorate navigation Skip top navigation and go to page navigation
National Science Foundation
design element
Search Awards
Recent Awards
Presidential and Honorary Awards
About Awards
Grant Policy Manual
Grant General Conditions
Cooperative Agreement Conditions
Special Conditions
Federal Demonstration Partnership
Policy Office Website

Award Abstract #1026606

SBIR Phase II: Nano-scale Engineering via Grid-scale Computing: Designing, Optimizing and Manufacturing Cancer Therapeutics

Div Of Industrial Innovation & Partnersh
divider line
Initial Amendment Date: August 24, 2010
divider line
Latest Amendment Date: April 2, 2014
divider line
Award Number: 1026606
divider line
Award Instrument: Standard Grant
divider line
Program Manager: Ruth M. Shuman
IIP Div Of Industrial Innovation & Partnersh
ENG Directorate For Engineering
divider line
Start Date: September 1, 2010
divider line
End Date: September 30, 2014 (Estimated)
divider line
Awarded Amount to Date: $603,399.00
divider line
Investigator(s): Steven Armentrout sarmentrout@parabon.com (Principal Investigator)
divider line
Sponsor: Parabon NanoLabs, Inc.
11260 Roger Bacon Drive
Reston, VA 20190-5203 (703)689-9689
divider line
divider line
Program Reference Code(s): 169E, 5373, 6850, 9139, HPCC
divider line
Program Element Code(s): 5373


This Small Business Innovation Research (SBIR) Phase II project will advance the development of new drug compounds for the treatment of glioma, which have been designed and constructed with an innovative combination of grid-powered, computer-aided design (CAD) software and DNA nano-fabrication technology. The compounds are self-assembling DNA nanostructures functionalized with molecular subcomponents for targeting and destroying malignant glioma (brain) tumors. Prognosis for glioma is poor because complete surgical resection is impossible and chemotherapy (being poorly selective) leads to collateral brain damage, hence treatments are needed that target and destroy glioma cells with high specificity.

The broader impacts of this research are the societal benefits associated with improved disease outcomes through the creation of revolutionary new nano-pharmaceuticals. The Company's efforts under this project are focused initially on creating an effective treatment for glioma, but the Company's Essemblix platform has the potential to be used to create compounds for a wide variety of 
indications. The ability to "plug and play" at the molecular level, made possible 
by PNL's computational and nano-fabrication technology, opens the door to the deliberate design and development of entirely new types of pharmaceutical materials that could address indications across a vast and diverse number of pharmaceutical and 
biotechnology market segments.


Please report errors in award information by writing to: awardsearch@nsf.gov.



Print this page
Back to Top of page
Research.gov  |  USA.gov  |  National Science Board  |  Recovery Act  |  Budget and Performance  |  Annual Financial Report
Web Policies and Important Links  |  Privacy  |  FOIA  |  NO FEAR Act  |  Inspector General  |  Webmaster Contact  |  Site Map
National Science Foundation Logo
The National Science Foundation, 4201 Wilson Boulevard, Arlington, Virginia 22230, USA
Tel: (703) 292-5111, FIRS: (800) 877-8339 | TDD: (800) 281-8749
  Text Only Version